An Investigator Initiated, Phase II Study of Linifanib in Patients With Advanced, Refractory Colorectal Cancer Expressing Mutated kRas.

Trial Profile

An Investigator Initiated, Phase II Study of Linifanib in Patients With Advanced, Refractory Colorectal Cancer Expressing Mutated kRas.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 28 Mar 2017

At a glance

  • Drugs Linifanib (Primary)
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 28 Mar 2017 Primary endpoint (Overall Response Rate (Complete Response + Partial Response) With a Target of at Least 15%) has not been met, according to the results published in the Investigational New Drugs
    • 28 Mar 2017 Results published in the Investigational New Drugs
    • 06 Mar 2013 Planned End Date changed from 1 Mar 2017 to 1 Mar 2018 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top